IMPACT Therapeutics Wins Final EC Marketing Authorization for Senaparib (Sepalna) – Highly Potent PARP1/2 Inhibitor Approved in the EU for Ovarian Cancer Maintenance

IMPACT Therapeutics (HKG: 7630) announced that the European Commission (EC) has granted final marketing authorization for senaparib (overseas brand name: Sepalna), the company's internally developed innovative drug, for the maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal…

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.

More News